Table 3 Relationship between absolute serum CA125 levels during chemotherapy and survival in ovarian cancer
From: Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature
First Author, Year, Study Place | Data Collection | Study Design | Sample Size | Groups being Compared | RR/HR, (95% CI), P-Value | Conclusion | Variables Adjusted for |
|---|---|---|---|---|---|---|---|
Colakovic S, 2000, Yugoslavia [51] | NA | Retrospective study | 222 | ≤ 35 U/ml & > 35 U/ml | < 0.0001 | The time needed for normalization of CA125 levels can divide patients into good and poor prognostic groups early during chemotherapy | Therapeutic response Karnofsky index, residual disease, tumor grade, CA125 half-life, CA125 kinetics |
Gadducci A, 1995, Italy [40] | 1986 to 1992 | Multicentric retrospective study | 225 | < 35 U/ml & > 35 U/ml before the third cycle of chemotherapy | NA | Serum CA125 half-life during early chemotherapy was an independent prognostic factor for both the achievement of a pathological complete response and the survival of patients with advanced epithelial ovarian cancer | FIGO stage, tumor grade, size of residual disease, serum CA125 before the first cycle of chemotherapy & serum CA125 half life |
Yedema CA, 1993, Netherlands [52] | July 1984 to Dec 1990 | Retrospective study | 60 | ≤ 35 U/ml & > 35 U/ml | 5.60 (1.16-27.1), 0.03 | There was a significant co relationship between serum CA125 levels after three courses of chemotherapy and survival in ovarian cancer. | Stage, histology, grade, tumor rest |